FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Cytokine topics
Antibodies
Inflammation
Specificity
Immunotherapy
Major Histocompatibility Complex
Compatibility
Combination Therapy
Histocompatibility
Immune Response
Monoclonal Antibody
Stimulator
Therapeutics
Immunostimulator
Monoclonal
Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cytokine patents



      
           
This page is updated frequently with new Cytokine-related patent applications. Subscribe to the Cytokine RSS feed to automatically get the update: related Cytokine RSS feeds. RSS updates for this page: Cytokine RSS RSS


Date/App# patent app List of recent Cytokine-related patents
10/23/14
20140316109
 Activated collagen scaffold materials and their special fused active restoration factors patent thumbnailActivated collagen scaffold materials and their special fused active restoration factors
Provided are activated collagen scaffold materials as well as their special fused active restoration factors useful for promoting tissue repair, such as bone damage repair or nerve injury repair. The special fused active restoration factors are fusion proteins comprising a collagen-binding domain (cbd) at n-/c-terminus of cytokines, wherein the collagen-binding domain is a polypeptide consisting of 7-27 amino acid residues with a conservative sequence shown in seq id no:12 at n-terminus.
10/23/14
20140315253
 Activated collagen scaffold materials and their special fused active restoration factors patent thumbnailActivated collagen scaffold materials and their special fused active restoration factors
Provided are activated collagen scaffold materials as well as their special fused active restoration factors useful for promoting tissue repair, such as bone damage repair or nerve injury repair. The special fused active restoration factors are fusion proteins comprising a collagen-binding domain (cbd) at n-/c-terminus of cytokines, wherein the collagen-binding domain is a polypeptide consisting of 7-27 amino acid residues with a conservative sequence shown in seq id no:4 at n-terminus.
10/23/14
20140314872
 Methods of use of culture supernatant obtained from mesenchymal stem cells from dogs and cats for treatment of organ dysfunction patent thumbnailMethods of use of culture supernatant obtained from mesenchymal stem cells from dogs and cats for treatment of organ dysfunction
A method of treatment of organ dysfunction using a supernatant containing molecules, cytokines and vesicles secreted from mesenchymal stem cells (msc) from animals is provided. The msc are cultured, and then centrifuged to separate them from the desired supernatant containing the molecules and vesicles that may be used for treatment.
10/23/14
20140314710
 Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment patent thumbnailIl-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment
A novel approach to discover new drugs against ms and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (il-12), the p40 monomer (p40), the p40 homodimer (p402), and the il-23.
10/23/14
20140311482
 Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors patent thumbnailRhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
The disclosure describes an aerosolizer with (i) means sized for intranasal or paranasal insertion that produces an aerosol from a material for delivery in close proximity to the upper airways, and (ii) the material comprising one or more proinflammatory cytokine inhibitor(s).. .
10/16/14
20140308747
 Ex vivo expansion of human hematopoietic stem cells patent thumbnailEx vivo expansion of human hematopoietic stem cells
Methods and kits for expanding the number of hematopoietic stem cells are provided. The methods comprise incubating cells in medium comprising isolated igfbp-2 and an angiopoietin-like protein (angptl).
10/16/14
20140308244
 Combination therapy for treatment of inflammatory demyelinating disease patent thumbnailCombination therapy for treatment of inflammatory demyelinating disease
Provided herein include combination therapies for the treatment of neurological inflammatory diseases, such as, for example, demyelinating autoimmune diseases, such as multiple sclerosis and neuromyelitis optica, etc. In various aspects and embodiments, the methods may include administering to a patient an effective dose of an inhibitor of an angiotensin-converting enzyme (ace) in combination with one or more second compounds, in one aspect, provided is a method of treating a demyelinating autoimmune disease (such as multiple sclerosis) that includes administering to a patient an effective dose of an inhibitor of an angiotensin-converting enzyme (ace) in combination with one or more compounds selected from the group consisting of a cytokine, a vitamin b, dimethyl fumarate (dmf, also referred to as bg-12) and fingolimod (gilenya)..
10/16/14
20140308239
 Chimeric cytokine formulations for ocular delivery patent thumbnailChimeric cytokine formulations for ocular delivery
Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery.. .
10/09/14
20140302070
 Novel pd1 isoforms, and uses thereof for potentiating immune responses patent thumbnailNovel pd1 isoforms, and uses thereof for potentiating immune responses
In one embodiment, the present invention provides a new isoform of human pd1 (Δ42pd1) that contains a 42-nucleotide in-frame deletion located at exon 2 domain. Δ42pd1 does not engage pd-l1/pd-l2, and can induce the production of pro-inflammatory cytokines in one embodiment, Δ42pd1 can be used as an intramolecular adjuvant to develop a fusion dna vaccine for enhancing antigen-specific cd8+ t cell immunity and for prevention of pathogenic infection and/or cancer.
10/09/14
20140301985
 Method of treating pancreatic and liver conditions by endoscopic-mediated (or laparoscopic-mediated) transplantation of stem cells into/onto bile duct walls of particular regions of the biliary tree patent thumbnailMethod of treating pancreatic and liver conditions by endoscopic-mediated (or laparoscopic-mediated) transplantation of stem cells into/onto bile duct walls of particular regions of the biliary tree
A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated.
10/02/14
20140295551
Protein markers associated bone marrow stem cell differentiation into early progentior cells
A novel cytosolic 58 kd phosphoprotein induced during bone marrow stem cell (bm) differentiation into dendritic cells (dc) during in vitro cultivation with the cytokine gm-csf by addition of antisera to an 82 kd bm cell surface protein generating cultivatable dendritic progenitor cells (dp). Genes, methods for preparing them as well as early dp have been provided.
10/02/14
20140294931
Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
Thyroid hormone antagonists and their nanoparticle formulations (nanotetrac™ or nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines.
10/02/14
20140294899
Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of determining whether the human subject is a glatiramer acetate responder by evaluating a biomarker selected from the group consisting of il-17 concentration, tnf-α concentration, il-2 concentration and ifn-γ concentration, or a combination thereof, in the blood of the human subject and administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the human subject only if the human subject is identified as a glatiramer acetate responder.. .
10/02/14
20140294874
Apoaequorin for reducing neuronal injury due to ischemia
The present invention provides apoaequorin-based compositions and methods for preconditioning neurons in a subject to reduce neuronal injury due to brain ischemia. Methods include the step of administering apoaequorin to neurons in a subject, wherein the apoaequorin initiates a change in cytokine expression levels resulting in a reduction of neuronal injury due to brain ischemia as compared to neurons not administered the apoaequorin.
10/02/14
20140294817
Polypeptides comprising fc fragments of immunoglobulin g (igg) and methods of using the same
Polypeptides comprising at least a first and second fc fragment of igg that can be used to induce a stimulated cell to produce the anti-inflammatory cytokine interleukin-10 and methods of using the same are disclosed herein.. .
10/02/14
20140294758
Light chain immunoglobulin fusion proteins and methods of use thereof
Provided are recombinant antibodies comprising one or more peptides fused to the c-terminus of the light chain constant region. Recombinant immunocytokines comprising a cytokine fused to the c-terminus of the light chain constant region are described and shown to be surprisingly active..
09/25/14
20140288661
Bone tissue engineering by ex vivo stem cells ongrowth into three-dimensional trabecular metal
Adult autologous stem cells cultured on a porous, three-dimensional tissue scaffold-implant for bone regeneration by the use of a hyaluronan and/or dexamethasone to accelerate bone healing alone or in combination with recombinant growth factors or transfected osteogenic genes. The scaffold-implant may be machined into a custom-shaped three-dimensional cell culture system for support of cell growth, reservoir for peptides, recombinant growth factors, cytokines and antineoplastic drugs in the presence of a hyaluronan and/or dexamethasone alone or in combination with growth factors or transfected osteogenic genes, to be assembled ex vivo in a tissue incubator for implantation into bone tissue..
09/25/14
20140288545
Methods for bilateral renal neuromodulation
Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
09/25/14
20140288531
Methods for bilateral renal neuromodulation
Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
09/25/14
20140286988
Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
1h-imidazo[4,5-c]quinolin-4-amines substituted at the 1-position with a substituent bearing a hydrazinobenzamide or hydrazinonicotinamide, a salt thereof, or a protected hydrazinobenzamide or hydrazinonicotinamide and conjugates made from such compounds are disclosed. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed..
09/25/14
20140286956
Modulating inflammasome activity and inflammation in the central nervous system
Compositions and methods for reducing inflammation in the central nervous system (cns) of a mammal that has been subjected to a stroke, traumatic injury to the cns such as traumatic brain injury (tbi), spinal cord injury (sci), or having an autoimmune or cns disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., asc, nalp1) in a mammalian inflammasome (e.g., the nalp1 inflammasome) and have use as treatments for sci, tbi, stroke, and autoimmune and cns diseases in a mammal.
09/18/14
20140275497
Methods for making cytokine compositions from tissues using non-centrifugal methods
Apparatus and methods for generating a solution rich in interleukin-1 receptor antagonist from a tissue comprising cytokine-producing cells. The apparatus can include a filter used with a separation system.
09/18/14
20140275279
Cysteamine in the treatment of fibrotic disease
Fibrotic diseases are characterized by the replacement of healthy tissue with scar tissue and extracellular matrix in response to tissue damage. Here we describe the reduction of extracellular matrix (ecm) deposition, interstitial fibroblasts, interstitial volume, expression of collagen i mrna and protein, expression of profibrotic cytokines and macrophage infiltration by cysteamine treatment..
09/18/14
20140275271
Novel modified curcumins and their uses
Wherein α, β, a, b, and r1-r4 are defined herein. This invention also provides pharmaceutical compositions comprising the above compounds, a method of accelerating the healing of a wound, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (mmp), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting nfκ-b activation in a population of cells..
09/18/14
20140275237
Beraprost isomer as an agent for the treatment of viral infection
In various embodiments the use of single isomer of beraprost as a therapeutic for the treatment of viral disease and other pathologies associated with the induction of a cytokine storm, such as influenza a viruses and the sars-causing coronvirus and mutations thereof is provided.. .
09/18/14
20140274895
Methods and non-immunogenic compositions for treating inflammatory disorders
Methods for making non-immunogenic anti-inflammatory cytokine compositions, comprising (a) obtaining a liquid comprising cytokine producing cells from a mammalian donor; (b) contacting the liquid with a solid extraction material to generate a composition rich in interleukin-1 receptor antagonist; and performing one or both of (i) removing cells from the composition and (ii) freezing the composition. The compositions comprise two or more of il1-ra, stnf-r1, stnf-rii, igf-i, egf, hgf, pdgf-ab, pdgf-bb, vegf, tgf-β1, and sil-1rii, compositions may also contain white blood cells and platelets..
09/18/14
20140274894
Methods for making cytokine compositions from tissues using non-centrifugal methods
Non-centrifugal methods for generating a solution rich in interleukin-1 receptor antagonist from a tissue comprising cytokine-producing cells. The solution rich in il-1ra can also include at least one of stnf-ri, stnf-rii, igf-i, egf, hgf, pdgf-ab, pdgf-bb, vegf, tgf-β1, and sil-1 rii..
09/18/14
20140271773
Medical device
The invention is directed to an improved medical device. In particular, the invention is directed to an improved medical device having a coating comprising novel cellular factor-containing solution compositions (referred to herein as cfs compositions), such cfs compositions including conditioned medium compositions obtained from culturing extraembryonic cytokine secreting cells (ecs cells), including amnion-derived cellular cytokine solution (referred to herein as accs) obtained from culturing amnion-derived multipotent progenitor (amp) cells, dispersed in a polymeric coating material..
09/18/14
20140271725
Small molecule enhancer for dendritic cell cancer vaccines
Disclosed is a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian dipeptidyl peptidase (dpp) iv activity and/or structural homologues thereof (dash) serine proteases. Also disclosed is a method of (a) increasing antitumor immunity, (b) stimulating or enhancing an immune response, (c) treating a condition characterized by abnormal cell proliferation, (d) increasing cytokine and/or chemokine production, or (e) stimulating or enhancing production of t-cells, in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian dash serine proteases.
09/18/14
20140271684
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-pd-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer..
09/18/14
20140271652
Immunologically active polypeptide
Disclosed are immunomodulatory polypeptides that elicit an unusual induced cytokine profile, compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed..
09/18/14
20140271580
Immunoprotective primary mesenchymal stem cells and methods
Immunoprotective primary mesenchymal stems cells (ip-msc) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The ip-msc express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (scfv), fab or f(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., il-2, il-4, il-6, il-7, il-9, and il-12), an interferon (e.g., ifnα, ifnβ, or ifnω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides..
09/18/14
20140271554
Reducing proinflammatory response
The present disclosure provides a method for suppressing a proinflammatory response by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce the levels of proinflammatory cytokines and may be a treatment for inflammatory disease, especially type 1 diabetes.
09/18/14
20140271553
Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising seq id no 4, seq id no 13, seq id no 17, seq id no 21, seq id no 24, seq id no 30, seq id no 31, seq id no 32, seq id no 51, seq id no 57, seq id no 60, and seq id no 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e.
09/18/14
20140271539
Novel use of members of il-10 cytokine family
The invention relates to a novel use of the members of the il-10 cytokine family in wound healing. Particularly, the invention relates to the use of the member of the il-10 cytokine family in the promotion of the proliferation and the migration of keratinocyte cells in wound healing..
09/11/14
20140256682
Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
A combination therapy for treating osteoarthritis is disclosed. The combination therapy includes the co-administration of a steroid and zoledronic acid.
09/11/14
20140256681
Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
A combination therapy for treating osteoarthritis is disclosed. The combination therapy includes the co-administration of a steroid and zoledronic acid.
09/11/14
20140255904
Modulating ischemic injury and preserving/storing tissue
The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs.
09/11/14
20140255346
Cns antigen-specific b cell, t cell and antibody assays and their uses in diagnosis and treatment of multiple sclerosis
Embodiments of this invention include methods for detecting in vitro the presence in peripheral blood mononuclear cells (pbmcs), and in serum or plasma, of antibodies reactive to and of lymphocytes that are responsive to cns antigens associated with multiple sclerosis (ms). These cns antigens include, but are not limited to whole brain lysate and the myelin antigens myelin basic protein (mbp), myelin oligodendrocyte glycoprotein (mog), mog peptides (mogps), proteolipid protein (plp), and plp peptides (plpps).
09/04/14
20140249219
Anti-obesity potential of calebin a
The present invention discloses the potential of calebin a in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of calebin a to favorably modulate biochemical markers associated with obesity.
09/04/14
20140249071
Enhanced anabolic cytokine production and delivery system
Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins).
09/04/14
20140248661
Zcytor19 polynucleotides, polypeptides, antibodies and methods of use
Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class ii cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo.
08/28/14
20140242694
Composition containing complex cytokines derived from ebv-infected b cells for inducing the maturation of dendritic cells
A composition for deriving the maturation of dendritic cells includes complex cytokines generated by the simulation, the expression of which is induced on ebv-infected b cells. The dendritic cell maturation process, which conventionally takes approximately 7 days, can be shortened to 2 days, thereby producing dendritic cells in a more economically advantageous and effective manner..
08/28/14
20140242159
Method for preparing a granulate formulation of pirfenidone and pharmaceutically acceptable excipients
A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient.
08/21/14
20140235829
Compositions and methods for regulation of tumor necrosis factor-alpha
The present invention relates to compositions and methods relating to an interleukin 18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (taif) or interleukin-32 (il-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression..
08/21/14
20140234451
Pharmaceutical composition comprising extract of puerariae flos for prevention and treatment of endometriosis
The present invention relates to a pharmaceutical composition containing puerariae flos extracts as active ingredients for preventing or treating endometriosis and the complications thereof. More particularly, puerariae flos extracts exhibit the activity of inhibiting the migration and adhesion of endometriosis cells, inhibiting the expressions of mmp-2 and mmp-9, which are factors associated with migration and adhesion, inhibiting the expression of cox-2, which is a factor associated with pain, and inhibiting the expression of mcp-1, which is a cytokine associated with inflammation, and rantes.
08/21/14
20140234297
Antibody constant domain regions and uses thereof
The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically binding the desired epitope) and (ii) an effector domain comprising a constant domain region which is derived from immunoglobulin of a first species which is a companion mammal, e.g. Dog, cat, or horse, having engineered substitutions at one or more positions and having an altered interaction with one or more fcrs or other ligands, and optionally enhanced effector function, relative to the parent constant domain region..


Popular terms: [SEARCH]

Cytokine topics: Antibodies, Inflammation, Specificity, Immunotherapy, Major Histocompatibility Complex, Compatibility, Combination Therapy, Histocompatibility, Immune Response, Monoclonal Antibody, Stimulator, Therapeutics, Immunostimulator, Monoclonal, Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cytokine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytokine with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.4164

3185

71 - 0 - 72